Consistent with an inhibitory role of DCYTB on FAK activation, analysis of two combined cohorts that together total 1610 breast cancer patients as well as the GOBO cohort (n = 1379) revealed that high DCYTB expression was associated with longer distant metastasis-free survival and longer relapse-free survival (both local and distant) (Fig. 1, Additional file 1: Figure S3). This evidence concerns the gene CYBRD1 and breast carcinoma.